| A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer (NCT05415215) | Hoffmann-La Roche | 2022-07-05 |
| Refining Local-Regional Therapy for IBC (NCT04636710) | Dana-Farber Cancer Institute | 2021-06-02 |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors (NCT04660929) | Carisma Therapeutics Inc | 2021-02-02 |
| Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer (NCT04030507) | Brigham and Women's Hospital | 2019-07-26 |
| Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer (NCT03515798) | Institut Paoli-Calmettes | 2018-08-29 |
| Denosumab as an add-on Neoadjuvant Treatment (GeparX) (NCT02682693) | GBG Forschungs GmbH | 2017-02-13 |
| A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer (NCT02623972) | Dana-Farber Cancer Institute | 2016-02-26 |
| A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) (NCT02125344) | GBG Forschungs GmbH | 2014-12-01 |
| Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer (NCT01938833) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2014-04-01 |
| Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients (NCT02221999) | RenJi Hospital | 2013-09-01 |
| Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer (NCT02199418) | RenJi Hospital | 2013-01-01 |
| Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) (NCT01583426) | GBG Forschungs GmbH | 2012-07-01 |
| Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer (NCT01525966) | City of Hope Medical Center | 2012-02-15 |
| Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer (NCT01426880) | GBG Forschungs GmbH | 2011-08-01 |
| Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer (NCT01880385) | Association Tunisienne de lutte Contre le Cancer | 2011-03-01 |
| Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer (NCT01417286) | Rutgers, The State University of New Jersey | 2010-12-21 |
| MUC1 Vaccine for Triple-negative Breast Cancer (NCT00986609) | Joseph Baar, MD, PhD | 2009-08-19 |
| Dose-escalation Study of Oral CX-4945 (NCT00891280) | Cylene Pharmaceuticals | 2009-02-01 |
| Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer (NCT00513695) | University of Washington | 2007-06-01 |
| Pilot Study of Inflammatory Breast Cancer in Egypt and Tunisia (NCT00344071) | National Cancer Institute (NCI) | 2004-09-08 |
| Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer (NCT00049114) | National Cancer Institute (NCI) | 2003-02-01 |
| Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer (NCT00016276) | National Cancer Institute (NCI) | 2001-05-01 |
| Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer (NCT02324088) | UNICANCER | 2000-10-01 |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (NCT00004074) | National Cancer Institute (NCI) | 1999-08-01 |
| Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer (NCT00003199) | Fred Hutchinson Cancer Center | 1997-11-01 |